PayPay Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

PayPay Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99K	Sell	4 -1	-20%	-$443	0.05%	169
2026 Q1	$2.18K	Sell	5 -1	-17%	-$466	0.08%	166
2025 Q4	$2.72K	Buy	6 +1	+20%	+$431	0.08%	163
2025 Q3	$1.92K	Buy	5 +1	+25%	+$418	0.07%	171
2025 Q2	$1.78K	Sell	4 -1	-20%	-$461	0.09%	157
2025 Q1	$2.75K	Sell	5 -3	-38%	-$1.4K	0.16%	125
2024 Q4	$3.22K	Buy	+8	New	+$3.71K	0.14%	126

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PayPay Securities's VRTX Position: Q2 2026 in Review

PayPay Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q2 2026, selling an estimated $443 and leaving 4 shares worth $1.99K. The position accounts for 0.05% of the portfolio, ranked #169.

PayPay Securities first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.22K in Q4 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

PayPay Securities held 4 shares of Vertex Pharmaceuticals worth $1.99K as of Q2 2026.
PayPay Securities sold 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
Vertex Pharmaceuticals made up 0.05% of PayPay Securities's portfolio in Q2 2026, its #169 holding.
PayPay Securities first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
PayPay Securities's Vertex Pharmaceuticals position peaked at $3.22K in Q4 2024.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on PayPay Securities's 13F filing for Q2 2026, filed 23 Jul 2026.